目的：观察奥洛他定滴眼液联合自体血清治疗蒿属花粉过敏性结膜炎的临床疗效。

方法：选取我院2016-06/2018-06蒿属过敏原检测结果为阳性的过敏性结膜炎患者305例610眼，随机分为对照组和观察组。对照组患者采用奥洛他定滴眼液治疗，观察组患者在对照组的基础上加用自体血清，均持续治疗2wk。比较两组患者治疗前后症状与体征总得分、临床疗效，观察患者治疗期间不良反应发生情况。

结果：治疗前，两组患者症状与体征总得分比较，差异无统计学意义(P>0.05)； 治疗后2wk，观察组患者症状与体征总得分低于对照组(P<0.05)，观察组患者临床疗效优于对照组(P<0.05)。两组患者不良反应发生率比较无差异(P>0.05)。

结论：奥洛他定滴眼液联合自体血清治疗蒿属花粉过敏性结膜炎的临床疗效确切，可有效改善患者的临床症状和体征，且安全性较高。

METHODS:Totally 305 patients with 610 eyes with allergic conjunctivitis and positive allergen test results of artemisia in our hospital were selected from June 2016 to June 2018, and randomly divided into the control group and the observation group. Patients in the control group were treated with olopatadine eye drops. Patients in the observation group were treated with autologous serum on the basis of the control group. Patients in both groups were treated continuously for 2wk. The total scores of symptoms and signs and clinical efficacy of the two groups were compared before and 2wk after treatment, and the adverse reactions during the treatment were observed.

RESULTS: Before treatment, there was no statistically significant difference in the total score of symptoms and signs between the two groups(P>0.05). Two weeks after treatment, the total score of symptoms and signs in the observation group was lower than that in the control group(P<0.05), and the clinical efficacy of the observation group was better than that of the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).

CONCLUSION: Olopatadine eye drops combined with autologous serum in the treatment of artemisia pollen allergic conjunctivitis has a definite clinical effect, which can effectively relieve the clinical symptoms and signs of patients with high security.